Frequently Asked Questions (FAQ)
About the Quantra System
Since launching the first cartridge in 2019, HemoSonics has expanded into mutiple hospitals across the United States, partnering with many of the most respected names in U.S. and global healthcare to improve patient outcomes and advance coagulation research.
While the full name is “the Quantra Hemostasis System,” some healthcare providers internally refer to it as “Quantra” for convenience. Both terms refer to the same advanced hemostasis solution.
Yes, a growing body of clinical evidence supports the use of the Quantra System. As of April 2025, there have been 56 publications across eight different clinical areas. Additionally, 67 abstracts have been presented at clinical conferences since 2020. Further, HemoSonics has conducted multiple clinical trials that were submitted and accepted by the FDA as part of the 510k review process.
Yes, clinical trials submitted to the FDA and conducted independently have demonstrated that the Quantra System is substantially equivalent to traditional thromboelastography and thromboelastometry and newer cartridge-based viscoelastic testing (VET) systems.
Yes, additional regulatory indications are in process and/or planned for across multiple disease states.
The Quantra System is the only cartridge-based viscoelastic testing system with FDA indications in the following specialties: Cardiovascular, Trauma, Liver Transplant, and Major Orthopedic Surgery.
No cartridge-based viscoelastic testing system is currently received FDA-cleared for use in pediatrics.
HemoSonics is committed to expanding its dossier of clinical and scientific evidence and continues to actively invest in generating additional clinical and economic evidence across multiple clinical segments.
About the Quantra System’s Features
No, the Quantra System is a cartridge-based system that eliminates the need for manual pipetting.
There are two cartridges available (QPlus and QStat). These two cartridges have the broadest clinical indications of any cartridge-based viscoelastic testing system – cardiovascular, trauma, liver transplant, and major orthopedic surgery.
No, both QPlus and QStat cartridges can be stored at room temperature.
Please contact HemoSonics for pricing information on the Quantra Hemostasis Analyzer, cartridges, or other ancillary products.
Yes, the Quantra System provides a holistic assessment of platelet function during coagulation, rather than measuring a specific activity of platelets inhibited by antiplatelet therapies. The PCS or Platelet Contribution to Clot Stiffness parameter reflects both platelet count and functionality – how platelets aggregate, contract, and contribute to the strength of a clot. This information is clinically relevant to the intraoperative or postoperative patient who is bleeding or at risk of bleeding.
Platelet Contribution to Clot Stiffness (PCS) is typically available in approximately 12.5 minutes (without the need for incubation) after test start, enabling clinical teams to quickly identify and treat a platelet deficiency pre, intra, or post-operatively.
Yes, the Quantra System features a remote viewer known as the Quantra Desktop Remote Viewer (QDRV). QDRV displays live and historical data on any Windows-based workstation within the facility. The technology is designed to allow you to retain control over your data, should you choose to view, export, print, or publish the information. It does not require an external server – your data is inside the hospital firewall.
No, the Quantra Desktop Remote Viewer (QDRV) does not require an annual licensing fee.
Yes, the Quantra System connects bi-directionally with traditional middleware applications in the laboratory and at the point of care. Typical applications include TELCOR QML, Abbott RALS, Siemens UniPOC, and Data Innovations DI, among others.
Yes, the Quantra System can connect to the hospital network via a wired ethernet connection or wirelessly with an Ethernet to Wi-Fi Bridge.
About Training and Service for the Quantra System
Yes, HemoSonics has a robust customer excellence team to support clinical users at every step of the product adoption cycle. Our comprehensive approach enables hospitals to fully scale the Quantra Hemostasis System. The program includes Installation & Validation support, Implementation Support with on-site training, Algorithm Education & Adoption Support, Clinical Affairs Support, Professional Education, and Business Reviews.
HemoSonics has conducted reader studies as part of the FDA submission process: After a short 30-minute training, users were able to correctly interpret results with greater than 95% proficiency.
Yes, HemoSonics’ customers can access clinical application specialists and field service engineers to ensure optimal uptime for our instruments.
Yes, HemoSonics also offers three e-learning courses (device operator, device administrator, and interpreter), which can be added to a customer’s learning management system (LMS). The SCORM files are available for download from the HemoSonics’ customer portal and are compatible with leading LMS technologies including MyLearning, HealthStream, Docebo, Cornerstone, and others.
Yes, the Quantra System has partnered with the College of American Pathologists (CAP) and Qualiris to offer proficiency testing solutions. The CAP program code is VES1, and the Qualiris program is the EQA Program for Quantra System with QPlus Cartridge (KT-0048).
About HemoSonics
Yes, HemoSonics is the fastest-growing company in the United States specializing in viscoelastic testing.
HemoSonics is a Stago Group company. Stago is a global leader in hemostasis and thrombosis, with over 2,500 employees.
HemoSonics products are manufactured in the United States.